Introduction/Aim. During the SARS-CoV-2 pandemic, there was a significant number of cases accompanied by thrombosis. The precise pathophysiological mechanism remains unclear. The importance of the fibrinolytic mechanism in maintaining physiological hemostasis led us to explore its potential contribution to COVID-19-induced thromboembolism. This study aimed to identify changes in the hemostasis at the time of admission of SARS-CoV-2-positive patients to the hospital and their influence on the disease outcome. Methods. The presented prospective study included 60, RT-PCR-confirmed patients hospitalized in the Covid units of the Clinical Center of Vojvodina. Platelet number, platelet aggregability, aPTT, PT, fibrinogen, D-dimer, and Euglobulin Clot Lysis Time (ECLT) were determined from blood samples. Participants were classified as those with preserved and suppressed primary hemostasis, those with physiological and increased thrombin activity, those with preserved and decreased fibrinolytic activity, and those with positive and negative disease outcomes. Results. Forty-four positive outcomes were observed (73.3%), while a negative outcome, including thromboembolic complications and death was present in 16 subjects (26.7%). Unconditional logistic regression revealed a mild negative influence of all investigated parameters on the disease outcome. For ECLT, OR was 1.084 with 95%CI 1.023 -1.160. The multivariate regression model showed that of all the investigated parameters, only ECLT was a significant predictor for negative outcome with a level of p < 0.001. Conclusion. The global assessment of the fibrinolytic mechanism is a useful predictor of disease outcome in SARS-CoV-2-positive patients at the moment of their admission to hospital.
References
1.
Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an Acute Inflammatory Disease. The Journal of Immunology. 2020;205(1):12–9.
2.
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine. 2020;8(6):e46–7.
3.
Liotta LA, Goldfarb RH, Brundage R. Effect of Plasminogen Activator (Urokinase), Plasmin, and Thrombin on Glycoprotein and Collagenous Components of Basement Membrane. Cancer Res. 1981;41(11):4629–36.
4.
Esmon C. Inflammation and the Activated Protein C Anticoagulant Pathway. Seminars in Thrombosis and Hemostasis. 2006;32(S 1):049–60.
5.
Weiler H. Regulation of inflammation by the protein C system. Critical Care Medicine. 2010;38:S18–25.
6.
Medcalf RL, Keragala CB. Fibrinolysis: A Primordial System Linked to the Immune Response. International Journal of Molecular Sciences. 22(7):3406.
7.
Wichmann D. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Annals of Internal Medicine. 2020;173(12):1030.
8.
Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, et al. Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany. International Journal of Legal Medicine. 2020;134(4):1275–84.
9.
Elsoukkary SS, Mostyka M, Dillard A, Berman DR, Ma LX, Chadburn A, et al. Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology. 2021;88(1):56–68.
10.
Heinz C, Miesbach W, Herrmann E, Sonntagbauer M, Raimann FJ, Zacharowski K, et al. Greater Fibrinolysis Resistance but No Greater Platelet Aggregation in Critically Ill COVID-19 Patients. Anesthesiology. 2021;134(3):457–67.
11.
Di Micco P, Russo V, Carannante N, Imparato M, Cardillo G, Lodigiani C. Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study. Journal of Clinical Medicine. 9(12):4134.
12.
Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19. Journal of Thrombosis and Haemostasis. 2020;18(6):1324–9.
13.
Naymagon L, Zubizarreta N, Feld J, van Gerwen M, Alsen M, Thibaud S, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thrombosis Research. 2020;196:99–105.
14.
Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, et al. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. Journal of the American College of Surgeons. 2020;231(2):193-203e1.
15.
Bachler M, Bösch J, Stürzel DP, Hell T, Giebl A, Ströhle M, et al. Impaired fibrinolysis in critically ill COVID-19 patients. British Journal of Anaesthesia. 2021;126(3):590–8.
16.
Blasi A, von Meijenfeldt FA, Adelmeijer J, Calvo A, Ibañez C, Perdomo J, et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID‐19 patients on anticoagulation. Journal of Thrombosis and Haemostasis. 2020;18(10):2646–53.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
